White paper ‘Towards a constructive dialogue on pharmaceutical pricing’

There is still a lot of unmet medical need that requires the combined effort and support of all stakeholders to develop new breakthrough therapies. Developing and getting these innovative therapies to patients results in growing pressure to healthcare budgets. At the same time, these healthcare systems need to remain affordable and accessible to all patients. In the past decade, pharmaceutical companies have experimented with innovative pricing schemes to ensure affordability and accessibility.

Despite these efforts, we still find ourselves in a deadlock in the pricing debate. It is time that pharma and payers start working together to find real solutions and to ensure patients have access to the best possible therapies for a fair price for all stakeholders.

Vintura, in collaboration with Lieven Annemans, professor in health economics at UGent, developed a framework to help pharma and payers start a new dialogue and explore where they might find common ground.

The framework provides a step-by-step approach for pharmaceutical companies and payers:

• Step 1: come to an agreement on what constitutes value
• Step 2: come to an understanding of the pricing criteria
• Step 3: agree on the price dynamic over time
• Step 4: agree on risk sharing and the payment scheme

This framework will enable pharmaceutical companies and payers to start a structured dialogue and explore where they might find common ground. The ultimate goal is to secure innovation at a sustainable cost and a “fair” price for all stakeholders.

Download your copy of the white paper here.

Co-author Lieven Annemans, professor in health-economics, about this publication: “It is time that pharma and payers start working together on pharma pricing to find solutions that balance the needs of pharmaceutical companies, payers and society. I am proud to be co-author of the attached paper.”